Key Segmentation
By Therapy Type
-
Cell Therapy
-
Gene Therapy
-
Tissue-Engineered Products
-
Combined ATMPs
By Service Type
-
Process Development
-
Manufacturing Services
-
Analytical & Quality Control Services
-
Fill-Finish Services
-
Regulatory Support Services
By Indication
-
Oncology
-
Rare Genetic Disorders
-
Cardiovascular Diseases
-
Neurological Disorders
-
Other Therapeutic Areas
By End-user
-
Biopharmaceutical Companies
-
Emerging Biotechnology Companies
-
Academic & Research Institutes
-
Healthcare Organizations
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
The ATMP CDMO Market is expected to grow at a CAGR of 21.65% during the forecast period.
Increasing development of cell and gene therapies, rising outsourcing activities, and growing demand for specialized advanced therapy manufacturing capabilities are major factors driving market growth globally.
The ATMP CDMO Market was valued at approximately USD 7.75 Billion in 2025.
Cell Therapy dominated the market in 2025 due to increasing commercialization of CAR-T therapies, regenerative medicine products, and stem cell-based therapeutic programs globally.
North America dominated the ATMP CDMO Market in 2025 due to strong biotechnology innovation, increasing clinical trial activity, advanced manufacturing infrastructure, and growing commercialization of cell and gene therapies.